Turkish Journal of Geriatrics 2003 , Vol 6, Issue 1
HORMONAL TREATMENT IN PROSTATE CANCER
Asıf YILDIRIM, Kamil ÇAM, Hakan ÖZVER, Atıf AKDAŞ
Marmara Üniversitesi Tıp Fakültesi, Üroloji Anabilim Dalı, İstanbul
Abant İzzet Baysal Üniversitesi Düzce Tıp Fakültesi, Üroloji Anabilim Dalı, Bolu
Üro-Tıp (Üroloji Tanı Merkezi)
Prostate cancer gains great public attention as its incidence is increasing with age. Since definitive treatment options are contemporarily available only for the organ confined disease, a great deal of effort has been utilised in order to provide early diagnosis. With the extensive usage of prostate specific antigen there has been a shift of patients towards localised prostate cancer. Nevertheless, a certain number of patients have metastatic disease either at initial presentation or during the follow-up period of a previous treatment modality. Although it is palliative hormonal treatment constitutes the mainstay treatment in the management of metastatic disease. However, there are a variety of different approaches for the hormonal treatment. Even, both the time of onset and the appropriate form of the hormonal therapy have been extensively debated without reaching a definitive conclusion. Generally, partial or total androgen blockage including medical or surgical castration was preferred in the initial management of metastatic disease. Additionally, several forms of hormonal treatment as adjuvant and neoadjuvant aims have been utilised particularly in research studies for the local disease. In this review, all aspects of hormonal treatment including its history and side effects were evaluated. One of the curial properties of long-term hormonal treatment particularly for the geriatric population is its association with osteoporosis and bone fracture. There fore, this has to be taken into cousideration in patients with loug ,term hormonal therapy. Keywords : Hormonal treatment, prostate cancer, osteoporosis, aging male.